AbbVie and Bristol-Myers Squibb (BMS) have entered a clinical trial collaboration to assess ABBV-399 in combination with Opdivo (nivolumab) to treat patients with non-small-cell lung cancer (NSCLC).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

AbbVie’s ABBV-399 (telisotuzumab vedotin) is an investigational, anti-c-Met antibody-drug conjugate currently being developed to target both c-Met-amplified and c-Met over-expressing tumours.

Opdivo is BMS’ programmed death-1 (PD-1) immune checkpoint inhibitor that leverages the body’s immune system to restore anti-tumour response.

Under the collaboration, the firms are currently conducting a Phase Ib trial for advanced c-Met over-expressing NSCLC patients who failed one previous line of chemotherapy.

The trial will investigate the tolerability and potential efficacy of the ABBV-399 and Opdivo combination.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

AbbVie oncology early discovery and development vice-president Tom Hudson said: “Therapeutic advances continue to be achieved every day and we are committed to exploring the potential of our investigational compounds with other approved treatments with the goal to deliver a significant impact to patients.”

“We look forward to continuing to partner our PD1 with AbbVie’s early and late-stage assets as a possible treatment option for patients with lung cancer.”

AbbVie is sponsoring the Phase Ib trial, which could be expanded for treatment of other solid tumours in the future.

Bristol-Myers Squibb oncology development head Fouad Namouni said: “We continue to explore the potential of novel combinations of medicines with Opdivo, and AbbVie’s investigational treatments will help evaluate the role of new targets in combination with immunotherapy.

“We look forward to continuing to partner our PD1 with AbbVie’s early and late-stage assets as a possible treatment option for patients with lung cancer.”

BMS has been evaluating Opdivo in a wide range of clinical trials across all phases, and the drug’s clinical development programme involved more than 25,000 subjects to date.

Image: Non-small-cell lung cancer. Photo: courtesy of Yale Rosen via Wikipedia.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact